Imatinib Sandoz (Imatinib)

Imatinib acts on malignant cells driven by BCR‑ABL, KIT or PDGFR signaling pathways, providing targeted therapy for several hematologic and solid tumors.

• Chronic myeloid leukemia (CML): reduces leukemic cell proliferation and induces cytogenetic remission.
• Philadelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL): improves survival by targeting BCR‑ABL‑positive blasts.
• Gastrointestinal stromal tumor (GIST): inhibits KIT‑driven tumor growth, leading to disease control.
• Other KIT‑positive tumors: provides antitumor activity in malignancies expressing KIT mutations.

• Imatinib selectively inhibits the ATP‑binding site of several tyrosine kinases, chiefly BCR‑ABL, KIT and platelet‑derived growth factor receptors (PDGFR). By blocking phosphorylation of these enzymes, the drug disrupts downstream signaling that drives cell proliferation and survival, leading to apoptosis of malignant cells that depend on these pathways. The inhibition is competitive and reversible, resulting in sustained suppression of oncogenic signaling while sparing most normal cells.

Imatinib may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Nausea: mild stomach upset.
• Edema: swelling of extremities.
• Fatigue: general tiredness.
• Diarrhea: loose stools.

Serious or Rare Side Effects

• Neutropenia: marked reduction in white blood cells.
• Hepatotoxicity: significant liver enzyme elevation.
• Cardiac failure: decreased heart pumping ability.

When prescribing Imatinib, clinicians should observe several safety measures to minimize risks.

• Monitor blood counts: perform regular complete blood count tests to detect neutropenia or anemia.
• Assess liver function: check hepatic enzymes before and during therapy.
• Evaluate cardiac status: perform baseline and periodic echocardiograms in patients with cardiac history.
• Avoid strong CYP3A4 inhibitors: concurrent use may increase drug exposure.
• Use caution in pregnancy: limited data; weigh benefits against potential fetal risk.
• Store at room temperature: keep in original packaging, protect from moisture and heat.

Imatinib interacts with several medicines that can alter its plasma concentration or increase toxicity.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may raise Imatinib levels and toxicity.
• Concomitant use with QT‑prolonging agents (e.g., sotalol): increases risk of cardiac arrhythmias.
• Anticoagulants such as warfarin: may enhance bleeding risk.

Moderate Interactions (Monitor Closely)

• Moderate CYP3A4 inducers (e.g., rifampin, carbamazepine): may lower Imatinib exposure.
• Acid‑reducing agents (e.g., proton pump inhibitors): can reduce absorption.
• CYP2C8 substrates (e.g., paclitaxel): may require dose adjustment.